Ultragenyx Pharmaceutical (RARE) EBITDA Margin Growth (1y) (2017 - 2026)
Ultragenyx Pharmaceutical (RARE) EBITDA Margin Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,609.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1,536.00 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ultragenyx Pharmaceutical | 2.77 Bn | 2.36 Bn | 106.00 Mn | -2,139.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,139.00 |
| Dec 31, 2025 | 1,963.00 |
| Sep 30, 2025 | -1,223.00 |
| Jun 30, 2025 | 1,434.00 |
| Mar 31, 2025 | 4,905.00 |
| Dec 31, 2024 | 2,155.00 |
| Sep 30, 2024 | 5,336.00 |
| Jun 30, 2024 | 5,746.00 |
| Mar 31, 2024 | 142.00 |
| Dec 31, 2023 | 4,508.00 |
| Sep 30, 2023 | 10,016.00 |
| Jun 30, 2023 | 2,188.00 |
| Mar 31, 2023 | 1,758.00 |
| Dec 31, 2022 | -1,792.00 |
| Sep 30, 2022 | -13,812.00 |
| Jun 30, 2022 | -6,331.00 |
| Mar 31, 2022 | -6,371.00 |
| Dec 31, 2021 | -1,804.00 |
| Sep 30, 2021 | -4,826.00 |
| Jun 30, 2021 | 701.00 |